Orphan drug outfit Hyperion Therapeutics has struck up a deal to acquire Israel's Andromeda Biotech, handing over as much as $570 million in cash and stock with eyes on a Phase III diabetes treatment.
Zimmer and Biomet signed a deal to combine forces and form an orthopedics giant in the $45 billion musculoskeletal industry. The companies had combined revenues of $7.8 billion in 2013.
As Big Pharma trades billions for whole business units, the deal-inclined Celgene has quietly paid $710 million to get its hands on a late-stage Crohn's disease contender in a deal that could spiral out to 10 figures.
French diagnostics giant bioMérieux closed its $450 million acquisition of Utah's BioFire Diagnostics only in January, but the investment is already beginning to pay off.
Valeant may think Allergan is a great buyout fit, as evidenced by the $47 billion bid it made for the California company Tuesday. But Allergan may feel differently--at least at the current offering price.
Allergan didn't waste any time in coming up with a poison pill to help thwart a hostile, $46 billion takeover attempt by Valeant CEO J. Michael Pearson and his hedge fund ally William Ackman. The board issued a shareholder rights plan on Tuesday evening giving its general investors the right to buy discounted shares once someone accumulates a threatening stake in the company of 10% or more.
As The Wall Street Journal reports, the Irvine, CA-based Allergan is the latest apple of deal-happy Valeant's eye. And allied with activist investor Bill Ackman--who recently flew under the radar to amass a 9.7% Allergan share--it might just have the heft to pull off a pickup, with or without Allergan's blessing.
Novartis CEO Joe Jimenez is on record saying he's "a big fan" of the company's consumer health business. But that doesn't mean he has to run it. The Swiss drugmaker gets to have its consumer health and hand it off, too, in a new joint venture with GlaxoSmithKline.
In an announcement full of surprises from Novartis and GlaxoSmithKline, the sale of the Swiss company's vaccines division to Glaxo may have been the least surprising part.
Why would GlaxoSmithKline sell most of its cancer business to Novartis? In today's deal announcement, that particular sale stands up for questioning.